AIDS Research and Treatment Current Opinion in HIV and AIDS, vol. 3, no. 6, pp. 620–626, 2008. [97] B. M. Best, A. M. Stek, M. Mirochnick et al., “Lopinavir tablet pharmacokinetics with an increased dose during pregnancy,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 54, no. 4, pp. 381–388, 2010. [98] J. van der Lugt, A. Colbers, J. Molto et al., “The pharma- cokinetics, safety and eﬃcacy of boosted saquinavir tablets in HIV type-1-infected Pregnant women,” Antiviral Therapy, vol. 14, no. 3, pp. 443–450, 2009. [99] N. von Hentig, G. Nı´sius, T. Lennemann et al., “Pharmacoki- netics, safety and eﬃcacy of saquinavir/ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy,” Antiviral Therapy, vol. 13, no. 8, pp. 1039–1046, 2008. [100] J. Ghosn, I. De Montgolﬁer, C. Corne´lie et al., “Antiretro- viral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeﬁciency virus type 1-infected women during pregnancy,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 4, pp. 1542–1544, 2008. [101] K. Squires, B. Olmscheid, and S. L. Zhang, “Tenofovir-DF (TDF)-containing antiretroviral (ARV) regimens for treat- ment of HIV in pregnancy: ﬁndings from the antiretroviral pregnancy registry (APR),” in Proceedings of the 49th Inter- science Conference on Antimicrobial Agents and Chemotherapy (ICAAC ’09), San Francisco, Calif, USA, 2009. [102] R. F. L’Homme, H. M. Nijland, L. Gras et al., “Clinical experience with the combined use of lopinavir/ritonavir and rifampicin,” AIDS, vol. 23, no. 7, pp. 863–865, 2009. [103] C. J. L. La Porte, E. P. H. Colbers, R. Bertz et al., “Phar- macokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 5, pp. 1553–1560, 2004. [104] G. D. Kirk, O. A. Lesi, M. Mendy et al., “The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa,” Hepatology, vol. 39, no. 1, pp. 211–219, 2004. [105] E. Collenberg, T. Ouedraogo, J. Ganame´ et al., “Seropreva- lence of six diﬀerent viruses among pregnant women and blood donors in rural and urban Burkina Faso: a comparative analysis,” Journal of Medical Virology, vol. 78, no. 5, pp. 683– 692, 2006. [106] F. Rouet, M. L. Chaix, A. Inwoley et al., “HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, C oˆte d’Ivoire: the ANRS 1236 study,” Journal of Medical Virology, vol. 74, no. 1, pp. 34–40, 2004. [107] U. Dumpis, E. C. Holmes, M. Mendy et al., “Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis,” Journal of Hepatology, vol. 35, no. 1, pp. 99–104, 2001. [108] J. K. Rockstroh, S. Bhagani, Y. Benhamou et al., “European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults,” HIV Medicine, vol. 9, no. 2, pp. 82–88, 2008. [109] R. Nu¨esch, J. Ananworanich, P. Srasuebkul et al., “Interrup- tions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection,” AIDS, vol. 22, no. 1, pp. 152–154, 2008. [110] I. F. Grigsby, L. Pham, L. M. Mansky, R. Gopalakrishnan, and K. C. Mansky, “Tenofovir-associated bone density loss,” 11 Therapeutics and Clinical Risk Management, vol. 6, no. 1, pp. 41–47, 2010. [111] J. N. Nkengasong, C. Maurice, S. Koblavi et al., “Field evaluation of a combination of monospeciﬁc enzyme-linked immunosorbent assays for type-speciﬁc diagnosis of human immunodeﬁciency virus type 1 (HIV-1) and HIV-2 infec- tions in HIV-seropositive persons in Abidjan, Ivory Coast,” Journal of Clinical Microbiology, vol. 36, no. 1, pp. 123–127, 1998. [112] F. Rouet, D. K. Ekouevi, A. Inwoley et al., “Field evaluation of a rapid human immunodeﬁciency virus (HIV) serial serologic testing algorithm for diagnosis and diﬀerentiation of HIV type 1 (HIV-1), HIV-2, and dual HIV-1-HIV-2 infections in West African pregnant women,” Journal of Clinical Microbiology, vol. 42, no. 9, pp. 4147–4153, 2004. [113] S. Matheron, F. Damond, A. Benard et al., “CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort,” AIDS, vol. 20, no. 3, pp. 459–462, 2006. [114] F. Damond, A. Benard, J. Ruelle et al., “Quality control assess- ment of Human Immunodeﬁciency Virus type 2 (HIV-2) viral load quantiﬁcation assays: results from an international collaboration on HIV-2 infection in 2006,” Journal of Clinical Microbiology, vol. 46, no. 6, pp. 2088–2091, 2008. [115] M. A. Bender, N. Kumarasamy, K. H. Mayer et al., “Cost- eﬀectiveness of tenofovir as ﬁrst-line antiretroviral therapy in India,” Clinical Infectious Diseases, vol. 50, no. 3, pp. 416–425, 2010.